期刊文献+

HER2基因RNA干扰质粒对SK-BR-3细胞增殖及凋亡的影响 被引量:3

RNAi silencing of HER2 gene induces apoptosis and antiproliferative effect of SK-BR-3 cell line
下载PDF
导出
摘要 目的探讨HER2基因高效RNA干扰质粒转染到SK-BR-3乳腺癌细胞后,对细胞的增殖及其凋亡的影响。方法采用脂质体转染法将针对HER2基因的高效RNA干扰质粒转染至乳腺癌细胞SK-BR-3中,通过细胞计数、MTT比色法、流式细胞术和Western blot检测PCNA增殖细胞核抗原,分析检测其对SK-BR-3细胞增殖、凋亡的影响。结果 MTT比色测定显示,HER2-shRNA2干扰质粒转染到SK-BR-3细胞后在48 h后现抑制,与空白对照组比抑制率分别为48 h 16.53%7、2h 39.03%9、6h 65.47%。流式细胞分析HER2-shRNA组细胞在96 h凋亡率达17.36%,明显高于阴性对照组的1.41%和空白对照组的1.25%(P<0.05)。结论将RNA干扰质粒HER2-shRNA2转染至SK-BR-3细胞中,可特异性地抑制SK-BR-3细胞的增殖并诱导其凋亡,为乳腺癌的靶向治疗奠定了基础。 Objective To examine the biologic effects of HER2 gene silencing on SKBR3 cells through the transfection of HER2-specific shRNA expression vector.Methods SK-BR-3 breast cancer cells overexpressing the HER2 gene were transfected with HER2-shRNA2 vector using Lipofectamine2000.After transfection the antiproliferative effect of HER2-shRNA2 was detected by MTT assay and apoptosis percentage was detected by flow cytometry.The expressions of proliferating cell nuclear antigen(PCNA) were evaluated by Western blot analysis.Results After transfection with HER2-shRNA2,inhibitory ratio of HER2-shRNA2 group was 16.53%(48h),39.03%(72 h),or 65.47%(96 h).After Seventy-two hours,apoptosis percentage of SK-BR-3 cells of transfected with HER2-shRNA2 was increased to 10.29% compared to that in negative control and blank control groups.Conclusion Silencing of HER2 gene by shRNA can inhibit proliferation and induce apoptosis in SK-BR-3 cells.These promising results suggest that shRNA targeted against human HER2 may be valuable tools as antiproferative agents against neoplastic cells.
机构地区 嘉兴学院医学院
出处 《中国实验诊断学》 北大核心 2011年第5期802-805,共4页 Chinese Journal of Laboratory Diagnosis
基金 嘉兴市科技计划项目(2009AY2059)
关键词 HER2基因 RNA干扰 乳腺癌 HER2 gene RNA interference breast cancer
  • 相关文献

参考文献10

  • 1Subik K,Lee JF,Baxter L,et al.The Expression Patterns of ER,PP,HER2,CK5/6,EGFR,Ki-67 and AR by immunohistochemical analysis in Breast Cancer Cell Lines[J].Breast Cancer,2010,20(4):35.
  • 2Scaltriti M,Baselga J.The epidermal growth factor receptor pathway:a model for targeted therapy[J].Clin Cancer Res,2006,12:5268.
  • 3Dykxhoorn DM,Palliser D,Lieberman J.The silent treatment:siRNAs as small molecule drugs[J].Gene Ther,2006,13:541.
  • 4Engelsen IB,Stefansson IM,Beroukhim R,et al.HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas[J].Int J Oncol,2008,32(2):307.
  • 5Mittendorf EA,Liu Y,Tucker SL,et al.A novel interaction between HER2/neu and cyclin E in breast cancer[J].Oncogene,2010,29(27):3896.
  • 6Tsutsui S,Ohno S,Murakami S,et al.Prognostic value of C-erbB2 expression in breast cancer[J].J Surg Oncol,2002,79(4):216.
  • 7Piccart-Gebhart MJ,Proctor M,Leyland-Jones B,Goldhirsch A,et al.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer[J].N Engl J Med,2005,353:1659.
  • 8Scheue W,Friess T,Burtscher H,et al.Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor model[J].Cancer Res,2009,69(24):9330.
  • 9Aigner A.Application of RNA interference:current state and prospects for siRNA-base strategies in vivo[J].J Appl Microbiol Biotechnol,2007,76(1):9.
  • 10Spidlen J,Shooshtari P,Kollmann TR,et al.Flow cytometry data standards[J].BMC Res Notes,2011,4(1):50.

同被引文献29

  • 1任淑华,张伟,曲平,刘义,王井伟,张林.RNA干扰C-erbB-2对肺腺癌细胞calu-3增殖的影响[J].癌症,2005,24(10):1173-1178. 被引量:8
  • 2Xia Q, Zhu Z, Wang J, et al.Expression and association of HER2 with prognosis in early-stage (T1-T2NOM0) non-small cell lung cancer[J]. Tumour Biol,2012,33(5): 1719-1725.
  • 3Hess KR, Esteva FJ.Effect of HER2 status on distant recurrence in early stage breast cancer[J]. Breast Cancer Res Treat,2013,137 (2) :449-455.
  • 4Turken O, Kunter E, Cermik H, et al.Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC)[J]. Neoplasma, 2003,50(4):257-261.
  • 5Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers [J]. International Journal of Cancer,2006,118(2):257-262.
  • 6Sharp PA.tkNA interference-2001[J].Genes Dev,2001,15 (5): 485-490.
  • 7杨成喜,卞宝祥,宋子焱.C-erbB-2过度表达对肺腺癌化疗疗效影响的临床观察[J].肿瘤基础与临床,2007,20(6):482-483. 被引量:3
  • 8Xia Q,Zhu Z,Wang J,et al.Expression and association of HER2 with prognosis in early-stage(T1-T2N0M0)non-small cell lung cancer[J].Tumour Biol,2012,33(5):1719-1725.
  • 9Takenaka M,Hanagiri T,Shinohara S,et al.The prog-nostic significance of HER2 overexpression in non-small cell lung cancer[J].Anticancer Res,2011,31(12):4631-4636.
  • 10Graus-Porta D,Beerli RR,Daly JM,et al.ErbB-2,the preferred heterodimerization partner of all ErbB receptors,is a mediator of lateral signaling[J].EMBO J,1997,16(7):1647-1655.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部